AngioDynamics Says FDA Lifts Warning Letters On Company's Facilities

(RTTNews) - AngioDynamics (ANGO), a provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, said that it received letters from the United Stated Food and Drug Administration (FDA) closing out warning letters received by the Company in May 2011 related to the company's Queensbury facility and November 2014 related to the Glens Falls and Marlborough facilities.

These latest actions, in addition to the November 17 announcement that the FDA had lifted a warning letter from January 2011, resolve all FDA warning letters against AngioDynamics.